Bonnie W Leung, Guihong Wan, Nga Nguyen, Hannah Rashdan, Shijia Zhang, Wenxin Chen, Sonia Cohen, Genevieve M Boland, Ryan J Sullivan, Riley M Fadden, Howard L Kaufman, Shawn G Kwatra, Nicole R LeBoeuf, Yevgeniy R Semenov
BACKGROUND: Previous studies have shown that combining immune checkpoint inhibitors (ICIs) with talimogene laherparepvec (TVEC) may improve antitumor responses. However, the risk of developing cutaneous immune-related adverse events (cirAEs) in patients treated with ICI and TVEC has not been studied. OBJECTIVE: To evaluate the differences in cirAE development between patients treated with ICI alone and both ICI and TVEC (ICI + TVEC). METHODS: Patients with cutaneous malignancy receiving ICI with or without TVEC therapy at the Massachusetts General Brigham healthcare system were included...
March 19, 2023: Journal of the American Academy of Dermatology